1. Home
  2. NCA vs ALLO Comparison

NCA vs ALLO Comparison

Compare NCA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCA
  • ALLO
  • Stock Information
  • Founded
  • NCA 1987
  • ALLO 2017
  • Country
  • NCA United States
  • ALLO United States
  • Employees
  • NCA N/A
  • ALLO N/A
  • Industry
  • NCA Investment Managers
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NCA Finance
  • ALLO Health Care
  • Exchange
  • NCA Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • NCA 280.8M
  • ALLO 252.9M
  • IPO Year
  • NCA N/A
  • ALLO 2018
  • Fundamental
  • Price
  • NCA $8.99
  • ALLO $1.21
  • Analyst Decision
  • NCA
  • ALLO Buy
  • Analyst Count
  • NCA 0
  • ALLO 12
  • Target Price
  • NCA N/A
  • ALLO $8.80
  • AVG Volume (30 Days)
  • NCA 59.6K
  • ALLO 3.1M
  • Earning Date
  • NCA 01-01-0001
  • ALLO 11-13-2025
  • Dividend Yield
  • NCA 3.92%
  • ALLO N/A
  • EPS Growth
  • NCA N/A
  • ALLO N/A
  • EPS
  • NCA N/A
  • ALLO N/A
  • Revenue
  • NCA N/A
  • ALLO N/A
  • Revenue This Year
  • NCA N/A
  • ALLO N/A
  • Revenue Next Year
  • NCA N/A
  • ALLO $100.00
  • P/E Ratio
  • NCA N/A
  • ALLO N/A
  • Revenue Growth
  • NCA N/A
  • ALLO N/A
  • 52 Week Low
  • NCA $7.77
  • ALLO $0.86
  • 52 Week High
  • NCA $9.12
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • NCA 58.92
  • ALLO 45.93
  • Support Level
  • NCA $8.91
  • ALLO $1.21
  • Resistance Level
  • NCA $9.01
  • ALLO $1.33
  • Average True Range (ATR)
  • NCA 0.10
  • ALLO 0.10
  • MACD
  • NCA -0.00
  • ALLO -0.02
  • Stochastic Oscillator
  • NCA 70.51
  • ALLO 4.41

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: